Sanofi’s (NASDAQ:SNY) growth is propelled by strong demand for its flagship drugs such as Dupixent (for asthma and eczema) ...

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical ...

More than 100 locations nationwide are participating in new clinical trials for a drug that shows promise for treating ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Regeneron Pharmaceuticals Inc. claims that a partner has broken a collaboration deal by refusing to reveal side deals for marketing ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Patsnap, a global leader in innovation and pharma intelligence, announced the launch of Hiro Life Sciences (Hiro LS), a groundbreaking AI assistant poised to redefine biopharmaceutical research and ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...

The Institute for Clinical and Economic Review (ICER) has announced plans to assess the clinical efficacy and value of ...

The battle over prescription drug discounts offered to hospitals under a federal program escalated as Sanofi became the third ...

Lead author Professor Sunil Badve, Professorial Fellow at The George Institute for Global Health and UNSW Sydney said the study expanded current knowledge about this class of drugs in key areas ...